Zosano Announces Pricing of Public Offering of Common Stock

Zosano Pharma (NASDAQ:ZSAN) has announced the pricing of the public offering of its common stock for gross proceeds of US$17.5 million.

As quoted in the press release:

The offering is expected to close on or about April 11, 2019, subject to the satisfaction of customary closing conditions. In addition, Zosano has granted the underwriters a 30-day option to purchase up to $2.625 million of additional shares of common stock.

Cantor Fitzgerald & Co. is the sole book-running manager for the offering.

BTIG, LLC and Maxim Group, LLC acted as financial advisors to Zosano in connection with the offering.

Zosano intends to use the net proceeds from the offering to fund its ongoing development and preparation for potential commercialization of Qtrypta™ (M207), and for working capital and general corporate purposes.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on March 27, 2019. The offering is being made only by means of a written prospectus and prospectus supplement that will form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by contacting Cantor Fitzgerald & Co. by mail at Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

Click here to read the full press release.